Sinovay announced that the scuchiumab injection developed by Jushi Biotech, a holding subsidiary, recently obtained top-line analysis data in a phase III clinical trial. This product is an all-human IgG1 monoclonal antibody developed by Jushi Biotech and is a biosimilar to Kesanting®. The approved indications for Kesanting® in China include plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa in the age of 6 and above, and its efficacy and safety have been widely recognized. Psoriasis is an immune-related chronic, inflammatory, and systemic disease. Currently, there are about 7 million psoriatic patients in China. Whole-human interleukin-17A is mainly produced by activated T cells and is a key molecule in the pathogenesis of psoriasis. Scuciumab can specifically bind IL-17A to block IL-17 receptor signaling, thereby inhibiting psoriatic inflammation.

Zhitongcaijing · 3d ago
Sinovay announced that the scuchiumab injection developed by Jushi Biotech, a holding subsidiary, recently obtained top-line analysis data in a phase III clinical trial. This product is an all-human IgG1 monoclonal antibody developed by Jushi Biotech and is a biosimilar to Kesanting®. The approved indications for Kesanting® in China include plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa in the age of 6 and above, and its efficacy and safety have been widely recognized. Psoriasis is an immune-related chronic, inflammatory, and systemic disease. Currently, there are about 7 million psoriatic patients in China. Whole-human interleukin-17A is mainly produced by activated T cells and is a key molecule in the pathogenesis of psoriasis. Scuciumab can specifically bind IL-17A to block IL-17 receptor signaling, thereby inhibiting psoriatic inflammation.